Latest & greatest articles for levothyroxine

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on levothyroxine or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on levothyroxine and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for levothyroxine

21. Effects of restricting levothyroxine dosage strength availability

Effects of restricting levothyroxine dosage strength availability Effects of restricting levothyroxine dosage strength availability Effects of restricting levothyroxine dosage strength availability Ain K B, Pucino F, Csako G, Wesley R A, Drass J A, Clark C, Ketteridge P, Crawford K, Banks S M, Dorworth T E Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results (...) and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Prescribing restricted versus nonrestricted dosage strength of levothyroxine to patients requiring thyroid hormone replacement or suppression of thyrotropin (TSH). The nonrestricted use of levothyroxine consisted of tablets containing 25, 50, 75, 100, 112, 125, 150, 175, 200, and 300 micrograms, while in the restricted-use, only five dosage strengths (25, 50, 100, 125, 150

NHS Economic Evaluation Database.1996

22. Suppressive therapy with levothyroxine for solitary thyroid nodules. A double-blind controlled clinical study.

Suppressive therapy with levothyroxine for solitary thyroid nodules. A double-blind controlled clinical study. 3295553 1987 07 23 1987 07 23 2016 11 23 0028-4793 317 2 1987 Jul 09 The New England journal of medicine N. Engl. J. Med. Suppressive therapy with levothyroxine for solitary thyroid nodules. A double-blind controlled clinical study. 70-5 Thyroid nodules are present in up to 50 percent of adults in the fifth decade of life. Patients are often treated with thyroxine in order to reduce (...) the size of the nodule, but the efficacy of thyrotropin-suppressive therapy with thyroxine remains uncertain. In this study, 53 patients with a colloid solitary thyroid nodule confirmed by biopsy were randomly assigned in a double-blind manner to receive placebo (n = 25) or levothyroxine (n = 28) for six months. Before treatment, pertechnetate-99m thyroid scanning showed that 22 percent of the nodules were functional, 25 percent hypofunctional, and 53 percent nonfunctional. High-resolution (10-MHz

NEJM1987